HIV-1 protease Inhibitors
2 drugsAbout HIV-1 protease
HIV-1 protease is an essential retroviral aspartyl protease required for HIV replication. It cleaves viral precursor polyproteins into functional proteins, enabling viral assembly and infectivity. Inhibiting HIV-1 protease prevents the maturation of new viral particles, halting further infection.
HIV-1 protease is a well-validated drug target due to its crucial role in the HIV lifecycle. Although there is currently no genetic evidence linking HIV-1 protease to specific diseases, its essential function makes it a significant target for drug development.
Two FDA-approved drugs target HIV-1 protease: VIRACEPT and PAXLOVID. Both are small molecule inhibitors developed by AGOURON PHARMS and Pfizer, respectively, for infectious disease indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Carcinoma Cervix,Stage III with only 1 trials.
Top HIV-1 protease Drugs
The competitive landscape includes AGOURON PHARMS and Pfizer, each with an approved drug.
Low market concentration suggests opportunity for new entrants, but high entry barriers due to established players.
HIV-1 protease Drug Modality Landscape
Modalities
Routes of Administration
HIV-1 protease is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
HIV-1 protease Clinical Trials 59 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 24 | 13 | 8 | 3 | 62% |
| Phase 2 | 22 | 12 | 6 | 4 | 67% |
| Phase 3 | 10 | 4 | 0 | 6 | 100% |
| Phase 4 | 3 | 1 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved HIV-1 protease drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting HIV-1 protease. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
HIV-1 protease Drug Approval Timeline (1997 - 2023)
The first drug, VIRACEPT, was approved in 1997, and the most recent, PAXLOVID, in 2023, spanning 27 years.
Recent approval of PAXLOVID indicates continued interest in this target, but potential market saturation warrants careful consideration.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 63 clinical trials targeting HIV-1 protease.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities